GFM
AVIR icon

GF Fund Management’s Atea Pharmaceuticals AVIR Stock Holding History

GF Fund Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.38K Buy
1,743
+209
+14% +$960 ﹤0.01% 562
2025
Q4 		$5.48K Sell
1,534
-220
-13% -$699 ﹤0.01% 621
2025
Q3 		$5.09K Sell
1,754
-342
-16% -$1.17K ﹤0.01% 608
2025
Q2 		$7.55K Hold
2,096
– – ﹤0.01% 596
2025
Q1 		$6.27K Buy
2,096
+323
+18% +$1.01K ﹤0.01% 610
2024
Q4 		$5.94K Buy
+1,773
New +$5.89K ﹤0.01% 601

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GF Fund Management's AVIR Position: Q1 2026 in Review

GF Fund Management increased its Atea Pharmaceuticals (AVIR) stake by 14% in Q1 2026, buying an estimated $960 and bringing the position to 1,743 shares worth $9.38K. The position accounts for ﹤0.01% of the portfolio, ranked #562.

GF Fund Management first reported a position in AVIR in Q4 2024 and has held it in 6 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • GF Fund Management held 1,743 shares of Atea Pharmaceuticals worth $9.38K as of Q1 2026.
  • GF Fund Management bought 209 Atea Pharmaceuticals shares in Q1 2026, an estimated $960.
  • Atea Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #562 holding.
  • GF Fund Management first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.